June 6 (Reuters) – Alexion Pharmaceuticals Inc said
its drug Soliris, already approved in the United States for the
treatment of two rare blood disorders, missed its primary goal
in a late-stage…
The post Alexion drug misses goal in late-stage trial appeared first on NASDAQ.